CD274 and squamous cell carcinoma: While the difference in the representation of histological subgroups may be due to reimbursement conditions (in the Czech Republic, combination therapy is not reimbursed for squamous cell carcinomas with high PD-L1 expression), the better ECOG PS and higher number of stages IVB patients may reflect the tendency to administer the combination therapy to patients who are more fit but have a larger tumor burden.